Molecular Partners 미래 성장

Future 기준 확인 2/6

Molecular Partners 의 수익은 연간 1.2% 감소할 것으로 예상되는 반면, 연간 수익은 57.8% 로 증가할 것으로 예상됩니다. 57.8% 연간. EPS는 연간 1.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -104.1% 로 예상됩니다.

주요 정보

-1.2%

수익 성장률

1.7%

EPS 성장률

Biotechs 수익 성장	28.5%
매출 성장률	57.8%
향후 자기자본 수익률	-104.1%
애널리스트 커버리지	Low
마지막 업데이트	01 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

OTCPK:MLLC.F - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CHF Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	26	-72	-74	-40	2
12/31/2025	5	-69	-77	-61	3
12/31/2024	5	-59	-71	-64	3
9/30/2024	6	-63	-63	-62	N/A
6/30/2024	8	-58	-63	-62	N/A
3/31/2024	7	-59	-60	-60	N/A
12/31/2023	7	-62	-60	-59	N/A
9/30/2023	9	-60	-58	-57	N/A
6/30/2023	9	-62	-63	-62	N/A
3/31/2023	20	-50	-63	-62	N/A
12/31/2022	190	118	117	119	N/A
9/30/2022	189	117	112	114	N/A
6/30/2022	190	118	111	113	N/A
3/31/2022	182	106	101	102	N/A
12/31/2021	10	-64	-92	-91	N/A
9/30/2021	9	-67	-71	-69	N/A
6/30/2021	6	-72	-55	-54	N/A
3/31/2021	7	-66	-47	-46	N/A
12/31/2020	9	-63	-31	-29	N/A
9/30/2020	11	-53	-47	-45	N/A
6/30/2020	14	-48	-58	-56	N/A
3/31/2020	17	-43	-30	-28	N/A
12/31/2019	20	-36	-3	-1	N/A
9/30/2019	17	-37	0	1	N/A
6/30/2019	14	-38	2	4	N/A
3/31/2019	12	-38	-20	-19	N/A
12/31/2018	10	-37	-43	-42	N/A
9/30/2018	17	-27	-41	-41	N/A
6/30/2018	23	-18	N/A	-39	N/A
3/31/2018	22	-24	N/A	N/A	N/A
12/31/2017	20	-25	N/A	-40	N/A
9/30/2017	17	-26	N/A	N/A	N/A
6/30/2017	16	-28	N/A	-38	N/A
3/31/2017	19	-22	N/A	N/A	N/A
12/31/2016	23	-19	N/A	-35	N/A
9/30/2016	27	-13	N/A	N/A	N/A
6/30/2016	31	-3	N/A	18	N/A
3/31/2016	30	-2	N/A	N/A	N/A
12/31/2015	29	0	N/A	26	N/A
9/30/2015	28	-6	N/A	N/A	N/A
6/30/2015	25	-11	N/A	-24	N/A
3/31/2015	26	-5	N/A	N/A	N/A
12/31/2014	27	-2	N/A	-11	N/A
12/31/2013	32	7	N/A	-14	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MLLC.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MLLC.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MLLC.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MLLC.F 의 수익(연간 57.8% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: MLLC.F 의 수익(연간 57.8% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MLLC.F (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Molecular Partners 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Molecular Partners AG Announces Executive Changes

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for ensovibep for the Treatment of COVID-19

Molecular Partners AG to Report Fiscal Year 2020 Results on Feb 26, 2021

Novartis AG (SWX:NOVN) acquired 6% stake in Molecular Partners AG (SWX:MOLN) for CHF 30 million.

Novartis Announces Collaboration with Molecular Partners AG to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19

Molecular Partners AG to Report Q1, 2021 Results on May 12, 2021

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of CHF 80.157291 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견